KAF156 belongs to a novel class of antimalarial molecules, the imidazolopiperazines, and in phase IIa trials was able to rapidly clear both P. falciparum and P. vivax parasites. On this basis, in 2017, KAF1561 will enter phase IIb combination studies with the antimalarial lumefantrine.
KAF156, a promising compound in MMV’s portfolio, has entered phase IIb patient trials in combination with an improved new formulation of the existing antimalarial lumefantrine. KAF156 is the first compound from a novel class of antimalarials, the imidazolopiperazines, and has the potential to be a game-changer in malaria elimination, rapidly curing malaria infections including resistant strains and blocking transmission of the parasite.
MMV and Novartis announced today that it will further expand their long-standing partnership. Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from MMV in collaboration with the Bill & Melinda Gates Foundation. This agreement sets out the terms and conditions for the development of KAF156 and its future availability to patients.